Clinical trial
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Feasibility, and Preliminary Efficacy of NouvNeu001 in Patients With Advanced Parkinson's Disease.
NCT07102342 is registered in ClinicalTrials.gov with iRegene Therapeutics Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Feasibility, and Preliminary Efficacy of NouvNeu001 in Patients With Advanced Parkinson's Disease.
- Lead sponsor
- iRegene Therapeutics Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- January 12, 2026
- Completion date
- September 30, 2032
- Enrollment
- 5 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.